Thomas W Weickert

List of Publications by Year
in descending order

| 105 papers | 9,437 citations | 66315
42 h-index | 45285
90 g-index |
|---|---|---|---|
| 112 all docs | 112 docs citations | 112 times ranked | 12783 citing authors |

#	Article	IF	Citations
1	Genome-wide association study identifies 30 loci associated with bipolar disorder. Nature Genetics, 2019, 51, 793-803.	9.4	1,191
2	Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics, 2021, 53, 817-829.	9.4	629
3	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biological Psychiatry, 2018, 84, 644-654.	0.7	627
4	Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell, 2018, 173, 1705-1715.e16.	13.5	623
5	Executive Subprocesses in Working Memory. Archives of General Psychiatry, 2003, 60, 889.	13.8	562
6	Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group. Molecular Psychiatry, 2018, 23, 1261-1269.	4.1	522
7	Cognitive Impairments in Patients With Schizophrenia Displaying Preserved and Compromised Intellect. Archives of General Psychiatry, 2000, 57, 907.	13.8	479
8	Antiâ€"N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 2505-2514.	6.7	233
9	Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Brocaâ€™s area volume. Molecular Psychiatry, 2016, 21, 1090-1098.	4.1	209
10	Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Molecular Psychiatry, 2013, 18, 1185-1192.	4.1	202
11	Brain regions underlying response inhibition and interference monitoring and suppression. European Journal of Neuroscience, 2006, 23, 1658-1664.	1.2	195
12	Accelerated Gray and White Matter Deterioration With Age in Schizophrenia. American Journal of Psychiatry, 2017, 174, 286-295.	4.0	168
13	Rethinking schizophrenia in the context of normal neurodevelopment. Frontiers in Cellular Neuroscience, 2013, 7, 60.	1.8	157
14	Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia. Molecular Psychiatry, 2020, 25, 2860-2872.	4.1	155
15	Increased macrophages andÂchanged brain endothelial cell gene expression in the frontal cortex of people with schizophrenia displaying inflammation. Molecular Psychiatry, 2020, 25, 761-775.	4.1	154
16	Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biological Psychiatry, 2004, 56, 677-682.	0.7	137
17	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. JAMA Psychiatry, 2021, 78, 47.	6.0	136
18	Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA. NeuroImage, 2020, 218, 116956.	2.1	135

#	Article	IF	Citations
19	Disambiguating ventral striatum fMRI-related bold signal during reward prediction in schizophrenia. Molecular Psychiatry, 2012, 17, 280-289.	4.1	127
20	Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder. Journal of Neuroinflammation, 2017, 14, 188.	3.1	125
21	Biomarkers in Schizophrenia: A Brief Conceptual Consideration. Disease Markers, 2013, 35, 3-9.	0.6	115
22	Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. Biological Psychiatry, 2022, 91, 313-327.	0.7	114
23	Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Molecular Psychiatry, 2015, 20, 685-694.	4.1	111
24	Habit and Skill Learning in Schizophrenia: Evidence of Normal Striatal Processing With Abnormal Cortical Input. Learning and Memory, 2002, 9, 430-442.	0.5	102
25	A quantitative review of the postmortem evidence for decreased cortical N-methyl-d-aspartate receptor expression levels in schizophrenia: How can we link molecular abnormalities to mismatch negativity deficits?. Biological Psychology, 2016, 116, 57-67.	1.1	99
26	Evidence for Network-Based Cortical Thickness Reductions in Schizophrenia. American Journal of Psychiatry, 2019, 176, 552-563.	4.0	97
27	Neural Mechanisms Underlying Probabilistic Category Learning in Normal Aging. Journal of Neuroscience, 2005, 25, 11340-11348.	1.7	95
28	Intra-dimensional/extra-dimensional set-shifting performance in schizophrenia: Impact of distractors. Schizophrenia Research, 2007, 89, 339-349.	1.1	95
29	Attention to Irrelevant Cues Is Related to Positive Symptoms in Schizophrenia. Schizophrenia Bulletin, 2013, 39, 575-582.	2.3	87
30	Transcranial direct current stimulation influences probabilistic association learning in schizophrenia. Schizophrenia Research, 2011, 131, 198-205.	1.1	85
31	White Matter Disruptions in Schizophrenia Are Spatially Widespread and Topologically Converge on Brain Network Hubs. Schizophrenia Bulletin, 2017, 43, sbw100.	2.3	85
32	Cognitive Subtypes of Schizophrenia Characterized by Differential Brain Volumetric Reductions and Cognitive Decline. JAMA Psychiatry, 2016, 73, 1251.	6.0	84
33	C-Reactive Protein: Higher During Acute Psychotic Episodes and Related to Cortical Thickness in Schizophrenia and Healthy Controls. Frontiers in Immunology, 2018, 9, 2230.	2.2	78
34	Serum testosterone levels are related to cognitive function in men with schizophrenia. Psychoneuroendocrinology, 2013, 38, 1717-1728.	1.3	70
35	Comparison of Cognitive Performances During a Placebo Period and an Atypical Antipsychotic Treatment Period in Schizophrenia: Critical Examination of Confounds. Neuropsychopharmacology, 2003, 28, 1491-1500.	2.8	69
36	Neural Correlates of Probabilistic Category Learning in Patients with Schizophrenia. Journal of Neuroscience, 2009, 29, 1244-1254.	1.7	69

#	Article	IF	Citations
37	Use of computerized assessment to predict neuropsychological functioning and emotional distress in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 55, 434-441.	6.7	66
38	Association of serum VEGF levels with prefrontal cortex volume in schizophrenia. Molecular Psychiatry, 2016, 21, 686-692.	4.1	62
39	The impact of premorbid and current intellect in schizophrenia: cognitive, symptom, and functional outcomes. NPJ Schizophrenia, 2015, 1, 15043.	2.0	60
40	Lack of false recognition in schizophrenia: a consequence of poor memory?. Neuropsychologia, 2004, 42, 546-554.	0.7	52
41	The Met66 allele of the functional Val66Met polymorphism in the brain-derived neurotrophic factor gene confers protection against neurocognitive dysfunction in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2006, 65, 1330-1335.	0.5	47
42	Reduced neural activity of the prefrontal cognitive control circuitry during response inhibition to negative words in people with schizophrenia. Journal of Psychiatry and Neuroscience, 2012, 37, 379-388.	1.4	46
43	Widespread Volumetric Reductions in Schizophrenia and Schizoaffective Patients Displaying Compromised Cognitive Abilities. Schizophrenia Bulletin, 2018, 44, 560-574.	2.3	44
44	Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 595-607.	1.8	40
45	An investigation of the integrity of semantic boundaries in schizophrenia. Schizophrenia Research, 2002, 53, 187-198.	1.1	37
46	Electrophysiological, cognitive and clinical profiles of at-risk mental state: The longitudinal Minds in Transition (MinT) study. PLoS ONE, 2017, 12, e0171657.	1.1	37
47	Relative Risk of Probabilistic Category Learning Deficits in Patients with Schizophrenia and Their Siblings. Biological Psychiatry, 2010, 67, 948-955.	0.7	36
48	First- and second-generation antipsychotic medication and cognitive processing in schizophrenia. Current Psychiatry Reports, 2005, 7, 304-310.	2.1	35
49	Adjunctive selective estrogen receptor modulator increases neural activity in the hippocampus and inferior frontal gyrus during emotional face recognition in schizophrenia. Translational Psychiatry, 2016, 6, e795-e795.	2.4	31
50	The Impact of Childhood Adversity on Cognitive Development in Schizophrenia. Schizophrenia Bulletin, 2020, 46, 140-153.	2.3	31
51	Selective Estrogen Receptor Modulation Increases Hippocampal Activity during Probabilistic Association Learning in Schizophrenia. Neuropsychopharmacology, 2015, 40, 2388-2397.	2.8	27
52	Peripheral BDNF: a candidate biomarker of healthy neural activity during learning is disrupted in schizophrenia. Psychological Medicine, 2015, 45, 841-854.	2.7	24
53	A splicing-regulatory polymorphism in DRD2 disrupts ZRANB2 binding, impairs cognitive functioning and increases risk for schizophrenia in six Han Chinese samples. Molecular Psychiatry, 2016, 21, 975-982.	4.1	23
54	Neutrophil–lymphocyte ratio – a simple, accessible measure of inflammation, morbidity and prognosis in psychiatric disorders?. Australasian Psychiatry, 2020, 28, 454-458.	0.4	22

#	ARTICLE	IF	CITATIONS
55	Testosterone and reward prediction-errors in healthy men and men with schizophrenia. Schizophrenia Research, 2015, 168, 649-660.	1.1	21
56	Brain antibodies in the cortex and blood of people with schizophrenia and controls. Translational Psychiatry, 2017, 7, e1192-e1192.	2.4	21
57	Peripheral complement is increased in schizophrenia and inversely related to cortical thickness. Brain, Behavior, and Immunity, 2022, 101, 423-434.	2.0	21
58	Grammatical processing in schizophrenia: Evidence from morphology. Neuropsychologia, 2010, 48, 262-269.	0.7	20
59	Significant differences in fMRI related activity between healthy adults and people with schizophrenia during reward-related prediction-errors. Molecular Psychiatry, 2012, 17, 235-235.	4.1	20
60	Testosterone Is Inversely Related to Brain Activity during Emotional Inhibition in Schizophrenia. PLoS ONE, 2013, 8, e77496.	1.1	19
61	Considering the role of adolescent sex steroids in schizophrenia. Journal of Neuroendocrinology, 2018, 30, e12538.	1.2	18
62	Obesity and brain structure in schizophrenia â€" ENIGMA study in 3021 individuals. Molecular Psychiatry, 2022, 27, 3731-3737.	4.1	17
63	Potential Role of Oestrogen Modulation in the Treatment of Neurocognitive Deficits in Schizophrenia. CNS Drugs, 2016, 30, 125-133.	2.7	16
64	Preliminary findings of four-week, task-based anodal prefrontal cortex transcranial direct current stimulation transferring to other cognitive improvements in schizophrenia. Psychiatry Research, 2019, 280, 112487.	1.7	16
65	Endogenous testosterone levels are associated with neural activity in men with schizophrenia during facial emotion processing. Behavioural Brain Research, 2015, 286, 338-346.	1.2	15
66	Raloxifene increases prefrontal activity during emotional inhibition in schizophrenia based on estrogen receptor genotype. European Neuropsychopharmacology, 2016, 26, 1930-1940.	0.3	15
67	Common polymorphisms in dopamine-related genes combine to produce a â€˜schizophrenia-likeâ€™ prefrontal hypoactivity. Translational Psychiatry, 2014, 4, e356-e356.	2.4	14
68	Raloxifene Improves Cognition in Schizophrenia: Spurious Result or Valid Effect?. Frontiers in Psychiatry, 2017, 8, 202.	1.3	14
69	Altered levels of immune cell adhesion molecules are associated with memory impairment in schizophrenia and healthy controls. Brain, Behavior, and Immunity, 2020, 89, 200-208.	2.0	14
70	A comparative study of colony takeover between queens of facultative and obligatory slave-making ants (Hymenoptera: Formicidae). Journal of Insect Behavior, 1990, 3, 813-817.	0.4	12
71	Dopaminergic therapy removal differentially effects learning in schizophrenia and Parkinsonâ€™s disease. Schizophrenia Research, 2013, 149, 162-166.	1.1	12
72	Impaired acquisition rates of probabilistic associative learning in frontotemporal dementia is associated with fronto-striatal atrophy. NeuroImage: Clinical, 2013, 2, 56-62.	1.4	12

#	Article	IF	Citations
73	What's Hot in Schizophrenia Research?. Psychiatric Clinics of North America, 2016, 39, 343-351.	0.7	12
74	Reward and punishment learning in schizophrenia and bipolar disorder. Behavioural Brain Research, 2020, 381, 112298.	1.2	12
75	Cognitive reserve attenuates age-related cognitive decline in the context of putatively accelerated brain ageing in schizophrenia-spectrum disorders. Psychological Medicine, 2020, 50, 1475-1489.	2.7	12
76	Peripheral NF-κB dysregulation in people with schizophrenia drives inflammation: putative anti-inflammatory functions of NF-κB kinases. Translational Psychiatry, 2022, 12, 21.	2.4	12
77	Increased plasma Brain-Derived Neurotrophic Factor (BDNF) levels in females with schizophrenia. Schizophrenia Research, 2019, 209, 212-217.	1.1	11
78	Virtual Ontogeny of Cortical Growth Preceding Mental Illness. Biological Psychiatry, 2022, 92, 299-313.	0.7	11
79	Neuregulin-1 (NRG1) polymorphisms linked with psychosis transition are associated with enlarged lateral ventricles and white matter disruption in schizophrenia. Psychological Medicine, 2018, 48, 801-809.	2.7	10
80	Exploring the moderating effects of dopaminergic polymorphisms and childhood adversity on brain morphology in schizophrenia-spectrum disorders. Psychiatry Research - Neuroimaging, 2018, 281, 61-68.	0.9	10
81	Transcriptional changes in the stress pathway are related to symptoms in schizophrenia and to mood in schizoaffective disorder. Schizophrenia Research, 2019, 213, 87-95.	1.1	10
82	Probabilistic association learning in frontotemporal dementia and schizophrenia. Cortex, 2013, 49, 101-106.	1.1	9
83	Differential effect of disease-associated ST8SIA2 haplotype on cerebral white matter diffusion properties in schizophrenia and healthy controls. Translational Psychiatry, 2018, 8, 21.	2.4	9
84	BDNF val66met genotype and schizotypal personality traits interact to influence probabilistic association learning. Behavioural Brain Research, 2014, 274, 137-142.	1.2	8
85	Cortisol-dehydroepiandrosterone ratios are inversely associated with hippocampal and prefrontal brain volume in schizophrenia. Psychoneuroendocrinology, 2021, 123, 104916.	1.3	7
86	The impact of smoking status on cognition and brain morphology in schizophrenia spectrum disorders. Psychological Medicine, 2022, 52, 3097-3115.	2.7	7
87	S33. REDUCTION IN PERIPHERAL C-REACTIVE PROTEIN LEVELS WITH CANAKINUMAB ADMINISTRATION IS RELATED TO REDUCED POSITIVE SYMPTOM SEVERITY IN PATIENTS WITH SCHIZOPHRENIA AND INFLAMMATION. Schizophrenia Bulletin, 2019, 45, S318-S318.	2.3	6
88	Frontal and Parietal Contributions to Probabilistic Association Learning. Cerebral Cortex, 2011, 21, 1879-1888.	1.6	5
89	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. Biological Psychiatry, 2019, 85, e35-e39.	0.7	5
90	Raloxifene augmentation in men and women with a schizophrenia spectrum disorder: A study protocol. Contemporary Clinical Trials Communications, 2020, 20, 100681.	0.5	5

#	Article	IF	Citations
91	Efficacy of Transcranial Direct Current Stimulation to Improve Insight in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Schizophrenia Bulletin, 2022, 48, 1284-1294.	2.3	5
92	Perceptual category judgment deficits are related to prefrontal decision making abnormalities in schizophrenia. Frontiers in Psychiatry, 2014, 4, 184.	1.3	4
93	Hormone modulation improves cognition in schizophrenia. Neuropsychopharmacology, 2016, 41, 384-385.	2.8	3
94	The effects of a muscarinic receptor 1 gene variant on cortical thickness and surface area in schizophrenia. Psychiatry Research - Neuroimaging, 2018, 280, 62-64.	0.9	3
95	Sex-Specific Associations of Androgen Receptor CAG Trinucleotide Repeat Length and of Raloxifene Treatment with Testosterone Levels and Perceived Stress in Schizophrenia. Molecular Neuropsychiatry, 2019, 5, 28-41.	3.0	3
96	Reply to: Implicit Memory in Schizophrenia: The Problem That Will Not Go Away. Biological Psychiatry, 2012, 71, e17.	0.7	2
97	Editorial: Schizophrenia: Human and Animal Studies. Frontiers in Behavioral Neuroscience, 2016, 10, 76.	1.0	2
98	Probabilistic association learning in schizophrenia. Current Opinion in Behavioral Sciences, 2018, 20, 1-8.	2.0	2
99	770. C-Reactive Protein as a Marker of Inflammation in Acute Psychosis and Schizophrenia. Biological Psychiatry, 2017, 81, S312-S313.	0.7	1
100	Second generation antipsychotics reduce treatment discontinuation rates compared with haloperidol. Evidence-Based Mental Health, 2008, 11, 115-115.	2.2	0
101	107. Reduction in Peripheral C-Reactive Protein Levels With Canakinumab Administration is Related to Reduced Positive Symptom Severity in Patients With Schizophrenia and Inflammation. Biological Psychiatry, 2019, 85, S44-S45.	0.7	0
102	F157. Transcriptional Changes in the Stress Pathway are Related to Symptoms in Schizophrenia and to Mood in Schizoaffective Disorder. Biological Psychiatry, 2019, 85, S273-S274.	0.7	0
103	P.095 Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions. European Neuropsychopharmacology, 2019, 29, S82.	0.3	0
104	M62. PERIPHERAL INFLAMMATION MARKERS IDENTIFY SUBSET OF PATIENTS WITH SCHIZOPHRENIA AND RELATED PSYCHOSES WHO HAVE INTELLECTUAL DECLINE FROM PREMORBID LEVELS. Schizophrenia Bulletin, 2020, 46, S158-S159.	2.3	0
105	Peripheral Inflammation Markers Identify a Subset of Patients With Schizophrenia and Related Psychoses who Display Intellectual Decline From Premorbid Levels. Biological Psychiatry, 2020, 87, S319.	0.7	0